• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RISPERIDONE Drug Record

  • Summary
  • Interactions
  • Claims
  • RISPERIDONE chembl:CHEMBL85 Approved

    Alternate Names:

    RISPERDAL M-TAB
    PERSERIS KIT
    LY03004
    R-64766
    R-64-766
    RCN-3028
    RISPERIDONE
    RISPERDAL CONSTA LONG ACTING
    LY-03004
    RISPERDAL CONSTA
    R-64,766
    N05AX08
    RISPERDAL
    RISPERDAL M
    RCN3028
    RISPERDAL QUICKLET
    RISPERIDONUM
    RISPERDAL®
    RISPERIDONA
    SEQUINAN
    RISPOLEPT
    RISPERIN
    RISPOLIN
    RISPERDONE
    rxcui:35636
    chembl:CHEMBL85
    pubchem.compound:5073
    chemidplus:106266-06-2
    drugbank:00734

    Drug Info:

    Drug Categories antipsychotic agents (second generation [atypical])
    FDA Approval 1993
    Drug Class small molecule
    Drug Indications Antipsychotic Agents
    Drug Class antipsychotic agents
    Year of Approval 1993
    Drug Categories adrenergic alpha-1 receptor antagonists
    Drug Categories adrenergic alpha-antagonists
    Drug Categories adrenergic antagonists
    Drug Categories agents that produce hypertension
    Drug Categories agents that reduce seizure threshold
    Drug Categories antidepressive agents
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a5 substrates
    Drug Categories cytochrome p-450 cyp3a7 substrates
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories dopamine d2 receptor antagonists
    Drug Categories histamine antagonists
    Drug Categories histamine h1 antagonists
    Drug Categories neurotoxic agents
    Drug Categories p-glycoprotein substrates
    Drug Categories potential qtc-prolonging agents
    Drug Categories qtc prolonging agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    Drug Categories serotonin 5-ht1 receptor antagonists
    Drug Categories serotonin 5-ht2 receptor antagonists
    Drug Categories serotonin receptor antagonists
    (7 More Sources)

    Publications:

    Keks et al., 1999, Risperidone (Risperdal): clinical experience with a new antipsychosis drug., Expert Opin Investig Drugs
    Nourian et al., 2008, Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function., Psychopharmacology (Berl.)
    Eltze, 1996, In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors., Eur. J. Pharmacol.
    Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
    Corena-McLeod M, 2015, Comparative Pharmacology of Risperidone and Paliperidone., Drugs R D
    Sleight et al., 1993, Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors., Eur. J. Pharmacol.
    Fenton et al., 2005, Risperidone: a review of its use in the treatment of bipolar mania., CNS Drugs
    Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
    Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
    Megens et al., 1994, Survey on the pharmacodynamics of the new antipsychotic risperidone., Psychopharmacology (Berl.)
    Gassó P et al., 2009, A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms., Pharmacogenomics J
    Saiz-Rodríguez M et al., 2018, Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants., Basic Clin Pharmacol Toxicol
    Suzuki Y et al., 2014, Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia., Pharmacogenomics J
    Vandenberghe F et al., 2015, Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort., Clin Pharmacokinet
    Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
    Choong E et al., 2013, Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects., J Clin Psychopharmacol
    Stevenson JM et al., 2016, Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes., Transl Psychiatry
    Schreiber et al., 1997, Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice., Neurosci. Lett.
    Lü et al., 2004, [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]., Di Yi Jun Yi Da Xue Xue Bao
    Erbağci et al., 2001, Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment., Mediators Inflamm.
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
    Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    Fang et al., 1999, Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4., Naunyn Schmiedebergs Arch. Pharmacol.
    Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
    Perez-Iglesias et al., 2008, Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment., J Clin Psychopharmacol
    Wei Z et al., 2013, Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy., J Clin Psychopharmacol
    Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
    Ma X et al., 2014, HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis., Int J Psychiatry Clin Pract
    Mulder H et al., 2009, HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study., J Clin Psychopharmacol
    De Luca V et al., 2007, HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis., Hum Psychopharmacol
    Ujike H et al., 2008, Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study., J Clin Psychiatry
    Canton et al., 1994, Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics., Neurosci. Lett.
    Mulder H et al., 2007, The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia., J Clin Psychopharmacol
    Risselada AJ et al., 2012, Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study., Pharmacogenomics J
    Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
    Dos Santos-Júnior A et al., 2016, Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents., Int J Endocrinol
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
    Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
    Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
    Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
    Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
    López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
    Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
    Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
    Catafau et al., 2006, Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response., Psychiatry Res
    Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
    Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
    Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
    Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
    Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
    Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
    Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
    Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
    Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
    Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
    Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
    Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
    Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
    Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
    Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
    Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
    Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
    Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
    Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
    David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
    Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
    Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
    Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
    Lane et al., 2004, Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function., Int. J. Neuropsychopharmacol.
    Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
    Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
    Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
    Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
    Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
    Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
    Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
    Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
    Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
    Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
    Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
    Remington et al., 2006, A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone., Am J Psychiatry
    Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
    Angelucci F et al., 2009, Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study., J Alzheimers Dis
    Maffioletti E et al., 2020, Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients., Drug Dev Res
    Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
    Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
    Calarge CA et al., 2009, Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents., Psychiatr Genet
    Atmaca et al., 2003, Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics., J Clin Psychiatry
    Gregoor JG et al., 2011, Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting., Pharmacogenomics
    Crisafulli C et al., 2012, Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics., Eur Arch Psychiatry Clin Neurosci
    Wei Z et al., 2012, A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients., J Psychopharmacol
    Kinkead et al., 2000, Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain., J. Pharmacol. Exp. Ther.
    Hongkaew Y et al., 2018, UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder., Pharmacogenomics J
    Cousein et al., 2007, P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Xiong Y et al., 2014, A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry
    Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
    Becker et al., 2008, Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment., Med Chem
    Lane HY et al., 2008, RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia., J Clin Psychopharmacol
    Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
    Fijal BA et al., 2009, Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia., Pharmacogenomics J
    Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci
    Cabaleiro T et al., 2014, Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers., Hum Psychopharmacol
    Zhao QZ et al., 2012, Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study., Psychiatr Genet
  • RISPERIDONE   GRID2

    Interaction Score: 1.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26905411


    Sources:
    PharmGKB

  • RISPERIDONE   PPA2

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   MSANTD1

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   GRM7

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26905411


    Sources:
    PharmGKB

  • RISPERIDONE   ANKK1

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20714340 23859574 18180754 18855532 18926547 18086475 18579277 26872113 17767146 23851570


    Sources:
    PharmGKB

  • RISPERIDONE   LEP

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19873684 12755665 21510767 23799528 26880915


    Sources:
    NCI PharmGKB

  • RISPERIDONE   CCL2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24495780


    Sources:
    PharmGKB

  • RISPERIDONE   DRD2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    15184239 9713903 20714340 19603545 15694263 28673279 23859574 15492764 18180754 17059881 16730699 11505224 17105675 15286066 10823405 18855532 18926547 16123753 18781856 11920858 12587665 11329406 21421319 991813 14610521 1839129 11132243 19179847 19944883 1969501 18086475 18579277 10395223 20375926 18781857 15077009 11752352 17989061 9858029 15830237 25943458 26872113 17767146 15140279 16513877 18354387 23851570 9672901 19396436 15146457 19273465 19853839 15907153 20194480 10862524 9918131 19373123 16513859


    Sources:
    TEND DTC PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • RISPERIDONE   EIF2AK4

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24751813


    Sources:
    PharmGKB

  • RISPERIDONE   EPM2A

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27092952


    Sources:
    PharmGKB

  • RISPERIDONE   MC4R

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22566560 23799528 23920449 27217270


    Sources:
    PharmGKB

  • RISPERIDONE   GRM3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19451915


    Sources:
    PharmGKB

  • RISPERIDONE   NTS

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10991962


    Sources:
    NCI

  • RISPERIDONE   TJP1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   RABEP1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • RISPERIDONE   SH2B1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • RISPERIDONE   TNFRSF11A

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   GHRL

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18480685


    Sources:
    NCI

  • RISPERIDONE   HTR2C

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inverse agonist
    Endogenous Drug? False
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    22967772 25152019 19142101 17702092 19193342 7898773 11132243 17632216 19997080 20680028 20504252 25943458 26880915 27217270


    Sources:
    PharmGKB DrugBank GuideToPharmacology ChemblInteractions

  • RISPERIDONE   NTF3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18473918


    Sources:
    NCI

  • RISPERIDONE   UGT1A7

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A10

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   FASN

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17052361


    Sources:
    NCI

  • RISPERIDONE   CNR1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23799528 20107430 20631561


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A8

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   FAAH

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20631561


    Sources:
    PharmGKB

  • RISPERIDONE   ADRA1B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    15992090 8925876 11132243 11752352 25943458 7691623 15907153


    Sources:
    DrugBank GuideToPharmacology

  • RISPERIDONE   CYP1A1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10048600


    Sources:
    NCI

  • RISPERIDONE   COMT

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19451915 22935916


    Sources:
    PharmGKB

  • RISPERIDONE   HTR2A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Specific Action of the Ligand Inverse agonist

    PMIDs:
    15992090 23859574 17316700 11132243 19494443 19997080 25943458 15907153 32462699


    Sources:
    TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • RISPERIDONE   UGT1A6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   DRD3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    7520908 19997080 7531353 19506579


    Sources:
    PharmGKB GuideToPharmacology

  • RISPERIDONE   HTR6

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    19997080


    Sources:
    PharmGKB GuideToPharmacology

  • RISPERIDONE   HRH4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23422377


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29955115


    Sources:
    PharmGKB

  • RISPERIDONE   ADRA1A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    15992090 18542932 8925876 11132243 25943458 7691623 15907153


    Sources:
    DrugBank GuideToPharmacology

  • RISPERIDONE   HTR7

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inverse agonist
    Endogenous Drug? False

    PMIDs:
    25943458


    Sources:
    DrugBank GuideToPharmacology

  • RISPERIDONE   HTR1D

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Direct Interaction? True
    Endogenous Drug? False

    PMIDs:
    11132243


    Sources:
    DrugBank GuideToPharmacology

  • RISPERIDONE   ADRA2B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11132243 25943458 15907153


    Sources:
    DrugBank

  • RISPERIDONE   HRH3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21652606


    Sources:
    PharmGKB

  • RISPERIDONE   CYP2E1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   ADRA2C

    Interaction Score: 0.03

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11132243 25943458 15907153


    Sources:
    DrugBank

  • RISPERIDONE   GRIN2B

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23859574


    Sources:
    PharmGKB

  • RISPERIDONE   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15567770 11545247


    Sources:
    NCI

  • RISPERIDONE   SLC6A4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23859574 20031235


    Sources:
    PharmGKB

  • RISPERIDONE   HTR1F

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • RISPERIDONE   HTR1A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    22120873 11132243


    Sources:
    PharmGKB DrugBank GuideToPharmacology

  • RISPERIDONE   HRH1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    15992090 11132243 25943458 9197279


    Sources:
    DrugBank GuideToPharmacology

  • RISPERIDONE   CYP1B1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   HTR1E

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • RISPERIDONE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29723928 24589909 26129906 29443543 19997080 23609392


    Sources:
    PharmGKB

  • RISPERIDONE   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18855532


    Sources:
    PharmGKB

  • RISPERIDONE   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26129906 23609392


    Sources:
    PharmGKB

  • RISPERIDONE   RGS4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18204343


    Sources:
    PharmGKB

  • RISPERIDONE   DRD1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    15992090 7520908


    Sources:
    DrugBank

  • RISPERIDONE   ADRA1D

    Interaction Score: 0.01

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • RISPERIDONE   HTR1B

    Interaction Score: 0.01

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • RISPERIDONE   ADRB2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   HTT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RISPERIDONE   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25042870


    Sources:
    PharmGKB

  • RISPERIDONE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC FDA

  • RISPERIDONE   KCNH2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RISPERIDONE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17337319


    Sources:
    NCI

  • DrugBank: DB00734

    • Version: 5.1.7

    Alternate Names:
    RISPERIDONE DrugBank Drug Name
    106266-06-2 CAS Number
    Act Risperidone Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Corena-McLeod M, 2015, Comparative Pharmacology of Risperidone and Paliperidone., Drugs R D

  • TEND: RISPERIDONE

    • Version: 01-August-2011

    Alternate Names:
    RISPERIDONE Primary Drug Name

    Drug Info:
    Year of Approval 1993
    Drug Class antipsychotic agents

    Publications:

  • TdgClinicalTrial: RISPERIDONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antipsychotic Agents
    Drug Class small molecule
    FDA Approval 1993

    Publications:

  • NCI: RISPERIDONE

    • Version: 14-September-2017

    Alternate Names:
    C29416 NCI drug code

    Drug Info:

    Publications:
    Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci
    Atmaca et al., 2003, Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics., J Clin Psychiatry
    Fang et al., 1999, Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4., Naunyn Schmiedebergs Arch. Pharmacol.

  • DTC: RISPERIDONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL85 ChEMBL Drug ID

    Drug Info:

    Publications:
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

  • PharmGKB: risperidone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
    Gassó P et al., 2009, A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms., Pharmacogenomics J
    Saiz-Rodríguez M et al., 2018, Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants., Basic Clin Pharmacol Toxicol

  • GuideToPharmacology: 135650903

    • Version: 29-September-2020

    Alternate Names:
    RISPERIDONE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Risperidone

    • Version: 2020.06.01

    Alternate Names:
    D01AZG TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL85

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL85

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Risperidone

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2021-04-13